Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 53Prostate Cancer Metastatic 6Neoplasm Metastasis 6Carcinoma, Transitional Cell 4Neoplastic Cells, Circulating 3Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Thrombocytosis 1Testicular Neoplasms 1Prostate Cancer, Hereditary, 7 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer, MCRPC 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1

Interventions

Flow Cytometry 5Therapeutics 4Cyclophosphamide 4Tacrolimus 3Polymerase Chain Reaction 3Methylprednisolone 3Methotrexate 3Antilymphocyte Serum 3thymoglobulin 2ruxolitinib 2liposomal amphotericin B 2fludarabine phosphate 2abiraterone 2Sunitinib 2Psychiatric Rehabilitation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Mycophenolic Acid 2Itraconazole 2Immunologic Techniques 2Immunoenzyme Techniques 2Imatinib Mesylate 2Dexamethasone 2Caspofungin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Analgesia 2Amplified Fragment Length Polymorphism Analysis 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × cabazitaxel × Genitourinary × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡